ArticleEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery2025
Late Outcomes of Thoracic Endovascular Aneurysm Repair Outside Versus Inside Instruction for Use.
Article in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate results of thoracic endovascular aortic repair (TEVAR) for thoracic aortic aneurysm (TAA) and to investigate outcomes based on adherence to manufacturer's instructions for use (IFUs).
methodsPatients treated with TEVAR in 4 tertiary hospitals between 2010 and 2021 were collected. Patients with connective tissue disorders, post-dissection TAAs, aortic coarctation and intramural haematomas were excluded. Both elective and urgent procedures were considered. Primary outcome was long-term survival. Secondary outcomes were: aortic-related reinterventions and late TEVAR failure.
resultsOut of 192 patients, 147 (76%) had endografts deployed inside IFU and 45 (24%) did not. Early outcomes were similar between groups with mortality rates of 6% inside IFU and 8.8% outside. Median follow-up was 36 months (interquartile range 20-63 months). Survival rate at 1, 3, and 5 years were 90%, 75%, and 61% for IFU group and 97%, 87%, and 66% for outside-IFU group (P = .55). Freedom from aortic-related reintervention at 1, 3, and 5 years were 94%, 87%, and 80% for IFU group and 88%, 78%, and 74% for outside IFU group (P = .04). TEVAR failure at 5 years occurred in 18 (13%) of inside IFU and 9 (22%) of outside IFU (P = .13).
conclusionsTEVAR is safe and effective in the long-term. Performing TEVAR outside IFU guidelines can still be acceptable but poses a higher risk of reintervention, especially for proximal landing zone violations. Close follow-up is essential to detect late failures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.